Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Symptoms  





2 Causes  





3 Diagnosis  





4 Treatment  



4.1  Relative effectiveness of treatments  







5 Research  



5.1  Phase IV  





5.2  Phase II  







6 See also  





7 References  





8 External links  














Psoriatic onychodystrophy






Türkçe
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 




In other projects  



Wikimedia Commons
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 

(Redirected from Psoriatic nails)

Psoriatic onychodystrophy
Other namesPsoriatic nails
A picture of a pair of feet in sandals. Some of the nails appear diseased.
Psoriasis of the toenails
SpecialtyDermatology
CausesPsoriasis
Differential diagnosisOnychomycosis
TreatmentMedications, radiation
Frequency10% to 78% of those with psoriasis

Psoriatic onychodystrophyorpsoriatic nails is a nail disease. It is common in those with psoriasis, with reported incidences varying from 10% to 78%. Elderly patients and those with psoriatic arthritis are more likely to have psoriatic nails.[1]: 781–2 

Symptoms[edit]

Psoriatic nails are characterized by a translucent discolouration in the nail bed that resembles a drop of oil beneath the nail plate.[2] Early signs that may accompany the "oil drop" include thickening of the lateral edges of the nail bed with or without resultant flattening or concavity of the nail; separation of the nail from the underlying nail bed, often in thin streaks from the tip-edge to the cuticle; sharp peaked "roof-ridge" raised lines from cuticle to tip; or separation of superficial layers of the nail followed by loss of patches of these superficial layers, leaving thin red nails beneath; or nail pitting–punctate changes along the nail plate surface.

Causes[edit]

The causes of nail psoriasis are unknown. It has been suggested that fungi may play a role.[3]

Diagnosis[edit]

The Nail Psoriasis Severity Index (NAPSI) is a numeric, reproducible, objective, simple tool for evaluation of nail psoriasis.[4] It evaluates several signs separately, each on a 1–3 scale: pitting, Beau's lines, subungual hyperkeratosis and onycholysis. A 2005 study proposed a modified NAPSI scale for persons with psoriasis and named the title of their publication "Modification of the Nail Psoriasis Severity Index".[5] Then, in 2007, a study found that there was a high level of inter-rater variability of the 2003 NAPSI scale and proposed another index which was, like the 2005 article, a modification of the 2003 article, and was named modified NAPSI.[6]

A 2008 study found that Cannavo's qualitative system[7] correlated with NAPSI (P<0.001) and is less time-consuming.[8]

Onycholysis: Separation of the nail plate from the nail bed

There is a risk of misdiagnosis with onychomycosis.

Treatment[edit]

There exist numerous treatments for nail psoriasis but there is little information concerning their effectiveness and safety.[9] Treatments include topical, intralesional, radiation, systemic, and combination therapies.

Relative effectiveness of treatments[edit]

Available studies lack sufficient power to extrapolate a standardized therapeutic regimen.[9]

As of April 2009, [needs update] an assessment of the evidence for the efficacy and safety of the treatments for nail psoriasis is in progress.[20]

A 2013 meta-analysis showed improvement of nail psoriasis with infliximab, golimumab, superficial radiotherapy, electron beam, and grenz rays compared to placebo.[22] Although systemic therapies have been shown to be beneficial, they may have serious adverse effects.[22] Topical treatments have not been well studied but may be beneficial.[22]

Research[edit]

Active clinical trials investigating nail psoriasis:[23]

Phase IV[edit]

Phase II[edit]

See also[edit]

References[edit]

  1. ^ James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin: Clinical Dermatology. (10th ed.). Saunders. ISBN 0-7216-2921-0.
  • ^ Kouskoukis, C.; Scher, R.; Ackerman, A. (1983). "The "oil drop" sign of psoriatic nails. A clinical finding specific for psoriasis". The American Journal of Dermatopathology. 5 (3): 259–262. doi:10.1097/00000372-198306000-00012. PMID 6625117.
  • ^ Szepietowski, C.; Salomon, J. (Nov 2007). "Do fungi play a role in psoriatic nails?". Mycoses. 50 (6): 437–442. doi:10.1111/j.1439-0507.2007.01405.x. ISSN 0933-7407. PMID 17944702. S2CID 37127086.
  • ^ Rich, P.; Scher, R. (2003). "Nail Psoriasis Severity Index: A useful tool for evaluation of nail psoriasis". Journal of the American Academy of Dermatology. 49 (2): 206–212. doi:10.1067/S0190-9622(03)00910-1. PMID 12894066.
  • ^ Parrish, CA; Sobera, JO; Elewski, BE (October 2005). "Modification of the Nail Psoriasis Severity Index". Journal of the American Academy of Dermatology. 53 (4): 745–6, author reply 746–7. doi:10.1016/j.jaad.2004.11.044. PMID 16198816.
  • ^ Cassell, S.; Bieber, J.; Rich, P.; Tutuncu, Z.; Lee, S.; Kalunian, K.; Wu, C.; Kavanaugh, A. (2007). "The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis". The Journal of Rheumatology. 34 (1): 123–129. PMID 17216680.
  • ^ Cannavò, S. P.; Guarneri, F.; Vaccaro, M.; Borgia, F.; Guarneri, B. (2003). "Treatment of Psoriatic Nails with Topical Cyclosporin: A Prospective, Randomized Placebo-Controlled Study". Dermatology. 206 (2): 153–156. doi:10.1159/000068469. PMID 12592084. S2CID 20866096.
  • ^ Kaçar, N.; Ergin, Ş.; Erdo?an, B. (2007). "The comparison of Nail Psoriasis Severity Index with a less time-consuming qualitative system". Journal of the European Academy of Dermatology and Venereology. 22 (2): 219–22. doi:10.1111/j.1468-3083.2007.02389.x. PMID 18211416. S2CID 41847018.
  • ^ a b Jiaravuthisan, M. M.; Sasseville, D.; Vender, R. B.; Murphy, F.; Muhn, C. Y. (2007). "Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy". Journal of the American Academy of Dermatology. 57 (1): 1–27. doi:10.1016/j.jaad.2005.07.073. PMID 17572277.
  • ^ Balbás, G. M.; Regaña, M. S.; Millet, P. U. (2009). "Tacalcitol ointment for the treatment of nail psoriasis". Journal of Dermatological Treatment. 20 (5): 308–310. doi:10.1080/09546630902787585. PMID 19367480. S2CID 208249471.
  • ^ Snchez Regaa, M.; Mrquez Balbs, G.; Umbert Millet, P. (2008). "Nail psoriasis: A combined treatment with 8 clobetasol nail lacquer and tacalcitol ointment". Journal of the European Academy of Dermatology and Venereology. 22 (8): 963–969. doi:10.1111/j.1468-3083.2008.02679.x. PMID 18410337.
  • ^ Fiallo, P. (2009). "Yellow nails as an adverse reaction to the topical use of 5-fluorouracil for the treatment of nail psoriasis". Journal of Dermatological Treatment. 20 (5): 299–301. doi:10.1080/09546630902773494. PMID 19363737. S2CID 42262387.
  • ^ Tzung, T.; Chen, C.; Yang, C.; Lo, P.; Chen, Y. (2008). "Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis". Acta Dermato-Venereologica. 88 (3): 279–280. doi:10.2340/00015555-0401. PMID 18480933.
  • ^ Rigopoulos, D.; Gregoriou, S.; Daniel, III, C. R.; Belyayeva, H.; Larios, G.; Verra, P.; Stamou, C.; Kontochristopoulos, G.; Avgerinou, G.; Katsambas, A. (2009). "Treatment of Nail Psoriasis with a Two-Compound Formulation of Calcipotriol plus Betamethasone Dipropionate Ointment". Dermatology. 218 (4): 338–341. doi:10.1159/000202179. PMID 19212110. S2CID 36470967.
  • ^ Lamerson, C.; Stevens, G.; Sax, K. (2008). "Treatment of nail psoriasis with efalizumab: A preliminary study". Cutis; Cutaneous Medicine for the Practitioner. 82 (3): 217–220. PMID 18856162.
  • ^ Rigopoulos, D.; Gregoriou, S.; Stratigos, A.; Larios, G.; Korfitis, C.; Papaioannou, D.; Antoniou, C.; Ioannides, D. (2008). "Evaluation of the efficacy and safety of infliximab on psoriatic nails: An unblinded, nonrandomized, open-label study". British Journal of Dermatology. 159 (2): 453–456. doi:10.1111/j.1365-2133.2008.08686.x. PMID 18565184. S2CID 205257408.
  • ^ a b Clinical trial number NCT00265096 for "A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis (GO-REVEAL)" at ClinicalTrials.gov
  • ^ Lee, Julia Yu-Yun (November 2009). "Severe 20-nail psoriasis successfully treated by low dose methotrexate". Dermatology Online Journal. 15 (11): 8. doi:10.5070/D32XF4V4PW. PMID 19951644.
  • ^ Saleem, K.; Azim, W. (2008). "Treatment of nail psoriasis with a modified regimen of steroid injections". Journal of the College of Physicians and Surgeons Pakistan. 18 (2): 78–81. PMID 18454890.
  • ^ Velema, Marieke; Hooft, Lotty; Lebwohl, Mark; Spuls, Phyllis I (2009). Spuls, Phyllis I (ed.). "Interventions for nail psoriasis". Protocols (1): CD007633. doi:10.1002/14651858.CD007633. hdl:2066/118676. PMID 23440816.
  • ^ a b Noiles, K.; Vender, R. (2009). "Nail psoriasis and biologics". Journal of Cutaneous Medicine and Surgery. 13 (1): 1–5. doi:10.2310/7750.2008.08012. PMID 19298765. S2CID 26612674.
  • ^ a b c de Vries, Anna Christa Q; Bogaards, Nathalie A; Hooft, Lotty; Velema, Marieke; Pasch, Marcel; Lebwohl, Mark; Spuls, Phyllis I (2013-01-31). "Interventions for nail psoriasis". Cochrane Database of Systematic Reviews (1): CD007633. doi:10.1002/14651858.CD007633.pub2. hdl:2066/118676. ISSN 1465-1858. PMID 23440816.
  • ^ clinicaltrials.gov
  • ^ Clinical trial number NCT00581100 for "Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis" at ClinicalTrials.gov
  • ^ Clinical trial number NCT00666354 for "Dose Response and Safety Study of Topical Methotrexate for the Treatment of Fingernail Psoriasis" at ClinicalTrials.gov
  • External links[edit]



    Retrieved from "https://en.wikipedia.org/w/index.php?title=Psoriatic_onychodystrophy&oldid=1187162807"

    Category: 
    Conditions of the skin appendages
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Wikipedia articles in need of updating from September 2020
    All Wikipedia articles in need of updating
     



    This page was last edited on 27 November 2023, at 21:23 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki